Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group.
Clin Cancer Res
; 17(21): 6858-66, 2011 Nov 01.
Article
em En
| MEDLINE
| ID: mdl-21908574
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Fenretinida
/
Recidiva Local de Neoplasia
/
Neuroblastoma
/
Antineoplásicos
Idioma:
En
Ano de publicação:
2011
Tipo de documento:
Article